A5049224808- RNA Interference and Gene Delivery
- Sarcoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- 3D Printing in Biomedical Research
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Innovative Microfluidic and Catalytic Techniques Innovation
- Cell death mechanisms and regulation
- DNA Repair Mechanisms
- Chronic Myeloid Leukemia Treatments
- Cancer-related Molecular Pathways
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Microfluidic and Bio-sensing Technologies
Institute for Bioengineering of Catalonia
2019-2025
Universitat de Barcelona
2023
CIBBIM-Nanomedicine
2019
Vall d'Hebron Institut de Recerca
2019
Universitat Autònoma de Barcelona
2019
Tumor recurrence, metastatic spread and progressive gain of chemo-resistance advanced cancers are sustained by the presence cancer stem cells (CSCs) within tumor. Targeted therapies with aim to eradicate these thus highly regarded. However, often use new anti-cancer is hampered pharmacokinetic demands. Drug delivery through nanoparticles has great potential increase efficacy reduce toxicity adverse effects. its production be based on intelligent design. Likewise, we developed polymeric...
Abstract ALK (anaplastic lymphoma kinase) rearrangements represent the third most predominant driver oncogene in non-small cell lung cancer (NSCLC). Although inhibitors are tyrosine kinase (TKIs) with longest survival rates cancer, complex systemic clinical evaluation and apoptotic death evasion of drug-tolerant persister (DTP) cells may limit their therapeutic response. We found that dynamic BH3 profiling (DBP) presents an excellent predictive capacity to ALK-TKIs, would facilitate use a...
Abstract Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with lack of specific biomarkers impairs development new therapies. Here, we utilize dynamic BH3 profiling (DBP), functional predictive biomarker measures net changes mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information guide use mimetics specifically inhibit...
Abstract Precision medicine is starting to incorporate functional assays evaluate anticancer agents on patient-isolated tissues or cells select for the most effective. Among these new technologies, dynamic BH3 profiling (DBP) has emerged and extensively been used predict treatment efficacy in different types of cancer. DBP uses synthetic peptides measure early apoptotic events (‘priming’) anticipate therapy-induced cell death leading tumor elimination. This predictive assay presents multiple...
Multiple targeted therapies are currently explored for pediatric and young adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment. However, this new armamentarium of faces an old problem: choosing the right treatment each patient. The lack predictive biomarkers is particularly worrying patients since it impairs implementation treatments in clinic. In study, we used functional assay dynamic BH3 profiling (DBP) to evaluate two BCP-ALL that could improve clinical outcome,...
Abstract Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with lack of specific biomarkers difficult development new therapies. We here utilize dynamic BH3 Profiling (DBP), functional predictive biomarker measures net changes mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. use this information guide mimetics specifically inhibit BCL-2...
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with survival rates exceeding 85%. However, 15% of patients will relapse; consequently, their decrease to below 50%. Therefore, several research and innovation studies are focusing on relapsed or refractory ALL (R/R ALL). Driven by this context following European strategic plan implement precision medicine equitably, Relapsed Network (ReALLNet) was launched under umbrella SEHOP in 2021, aiming connect bedside patient...